Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
CAMBRIDGE, Mass., Feb. 27, 2017 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in March. Details of the presentations are as follows:
| Cowen & Company 37th Annual Healthcare Conference | |||
| Date: | Monday, March 6, 2017 | ||
| Time: | 2:40 p.m. ET | ||
| Location: | Boston | ||
| Barclays Global Healthcare Conference 2017 | |||
| Date: | Thursday, March 16, 2017 | ||
| Time: | 9:30 a.m. ET | ||
| Location: | Miami | ||
Live webcasts of the presentations will be available on the Investors & Media section of the Editas website at www.editasmedicine.com. Archived replays will be available for approximately 30 days following the respective presentations.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 [email protected]
